Verification evidence is still being completed.
PDF / print export
Myria Biosciences AG
Basel, Switzerland
- Verified lead
- Steven Schmitt
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
- Review cycle
- 24 April 2026
- Full address
- Basel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Myria Biosciences pre-seed announcement naming Steven Schmitt as CEO.
- Editorial note
- Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
ETH Zurich spin-off, Public CEO disclosure, Pre-seed financing record
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Basel, Switzerland
Myria Biosciences AG
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets · Pre-seed research operations
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
- Lead
- Steven Schmitt (verified ↗)
- Address
- Basel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298) (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Pre-seed research operations
- Capabilities
- AI-Designed Microbial Strain Engineering · Synthetic Biology Platform · High-Throughput Drug Discovery
- Founded
- 2018
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED APRIL 2026
Steven Schmitt
Chief Executive Officer
Full addressBasel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
North Data registry record for Myria Biosciences AG in Basel (CHE-386.417.298).
Open sourcePre-seed research operations
Basel, Switzerland. Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets. Review completed on 24 Apr 2026.
Swissmedic and EMA for future oversight
ETH Zurich spin-off, Public CEO disclosure, Pre-seed financing record
Synthetic Biology, AI-Designed Microbes, and Drug Discovery for Undruggable Targets
Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing.
Editorial note
Myria Biosciences is an ETH Zurich spin-off with a named CEO, Basel and UK operations, and a closed June 2024 pre-seed financing supporting a synthetic biology plus AI drug-discovery platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
AI-Designed Microbial Strain Engineering
Synthetic Biology Platform
High-Throughput Drug Discovery
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Synthetic biology platform
AI-guided drug-discovery workflow
Basel and UK operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Myria Biosciences AG located?
- Myria Biosciences AG operates from Basel, Switzerland (registered seat per Swiss commercial registry CHE-386.417.298), Basel, Switzerland.
- Who runs Myria Biosciences AG?
- Myria Biosciences AG is led by Steven Schmitt, Chief Executive Officer. Verified 24 Apr 2026.
- What does Myria Biosciences AG do?
- Basel ETH Zurich spin-off combining AI and synthetic biology for undruggable-target drug discovery with a named CEO and closed 2024 pre-seed financing. Core capabilities: AI-Designed Microbial Strain Engineering, Synthetic Biology Platform, High-Throughput Drug Discovery.
Editorial context
Related technical briefs
Briefs that name Basel as a covered market or city.